onconova inc ontx hold na pt inspir continu enrol increas downgrad
 buy pt potenti winner tax reform busi invest
buy-back opportun rais pt analyst stephen anderson full summari
juno inc juno buy pt juno kite analyst jason mccarthi ph full
 buy pt ep match consensu rais ep estim due new
tax law reiter buy price analyst michael diana full summari
aeterna zentari inc aez buy pt announc deal term look pretti
corpor event call maxim salesperson inform
unit health product inc ueec ndr nyc ceo doug beplat wed thu feb
dineequ inc ndr san francisco ceo stephen joyc interim cfo gregori kalvin execut
director ir ken dipte mon feb
keyw hold corp keyw cover kinstling ndr san francisco ceo weber wed thu feb
nic inc cover kinstling ndr nyc cfo steve kovzan vice-president corpor commun
juno kite
juno share rose yesterday base sever report compani
could acquir partner celgen celg nr juno valuat
pull back come decemb exceed pre-
peak near kite valuat prior
acquir gilead buy question
valuat could juno acquir sever factor consid
celgen stake juno celgen put juno ex-u right
acquir stake compani celgen acquir
remain even valu suggest juno valuat
could higher compani closer
first car-t approv today three year ago
similar kite view juno pipelin car-t candid similar
size scope kite extend beyond hematolog
malign solid tumor like yescarta alon could gener
outyear revenu eu factor
china juno like kite joint ventur chines pharma
revenu fair valu suggest juno valuat could
near takeout valu kite higher
scarciti valu juno remain unencumb first-mov car-t
compani oncolog treatment paradigm shift toward integr
cell therapi juno may ideal target takeout larg pharma
establish like gilead major cell therapi player space
current valuat like compani like celgen
would pay premium acquir juno juno side unlik
compani go acquir current valuat discount
valuat less risk juno valuat metric factor success
 eu relapsed/refractori cell cancer well
platform valu discount rate support valuat current
rang howev consid similar kite gilead
paid scarciti valu celgen possibl acquir compani
bidder move closer potenti approv see less risk
lower discount rate price target climb
valuat near
transcend juno focu demonstr
efficaci nhl compar kite/gilead novarti shown well
similar safeti profil importantli case cerebr edema either data
on-going transcend trial octob present
patient treat two dose level cell cell full analysi
patient includ subtyp non-hodgkin lymphoma includ dlbcl tfl cll/
mzl pmbcl core group analysi includ patient dlbcl tfl
full analysi orr cr initi month
patient orr cr core group analysi orr
cr month orr patient
cr data stratifi two dose level patient
receiv dose level receiv dose level dose level orr
cr month orr cr dose level
dose pivot arm studi patient three month
orr cr patient month follow-up
orr cr pivot arm trial enrol
data updat expect patient reach month mark
click full note
potenti winner tax reform busi
invest buy-back opportun rais pt
maintain buy rate chipotl mexican grill rais price
target ahead compani releas decemb
result tuesday februari
argu particularli strong beneficiari corpor tax reform
expect manag invest busi buy back share
expect benign food cost provid addit boost ep
although lower ep estim rais
ep estim ep estim
primarili account lower tax rate
despit recent sale volatil still argu pullback share
provid opportun investor particip compani recoveri
argu particularli strong beneficiari corpor tax reform
expect manag invest busi buy back share assum
combin corpor tax rate pre-reform assumpt
rate estim reduc corpor tax rate alon would rais annual
ep per share much per share
howev estim actual annual ep upsid closer
believ manag use proce
reduc tax invest food particularli new item retain labor increas incent
sg c-level restaurant-level manag fund initi enabl tech-
enabl sale moreov expect manag acceler buyback
estim add ep much ep
estim reduct combin corpor tax rate add
annual ep els equal
expect benign food cost provid addit boost ep
accord model y/i reduct food cost add much
ep model lower cost protein avocado
although lower ep estim rais
ep estim ep estim
primarili account lower tax rate despit addit report
ill colder-than-usu weather quarter still believ manag
posit comp result comp vs prior forecast
model inflect point two-year stack comp march
would mark first time two year post posit two-year
stack comp forecast assum mid-single-digit comp growth
despit recent sale volatil still argu pullback share provid
opportun investor particip compani recoveri still
anticip return robust sale earn growth next quarter
believ retreat commod cost follow higher cost restaurant-
level effici gain reinforc margin expans multipli forward
price-to-earnings target ep estim arriv price target
round correspond forward ev/ebitda ratio
long-run averag garner prior coli outbreak
cmg short float percentag total float
weight industri averag better-than-expect result updat guidanc
head potenti trigger short-cov ralli
click full note
inspir continu enrol increas
downgrad hold
onconova announc independ data monitor committe
dmc recommend inspir phase studi rigosertib
myelodysplast syndrom md continu increas enrol
patient posit reaction
stock view base trial stop futil
howev patient mean time cost compani
cash per quarter burn rate requir need rais capit
regardless interim analysi lower rate hold
buy
sever scenario could play interim
analysi futil continu trial plan increas trial size focu
subgroup high risk vhr patient stop trial efficaci
increas trial enrol possibl though increas size
rais question trial design assumpt
recal inspir current trial design base prior trial on-
time prior trial subgroup analysi high risk patient
on-tim vs inspir inspir use random on-tim
patient enrol inspir trial similar enrol
point use on-tim subgroup analysi howev on-tim show
statist signific surviv benefit point wherea inspir appear
off-track hope addit patient inspir
result efficaci signal observ interim analysi data
blind reach statist signific end trial endpoint
trial remain unchang reach valu overal surviv either
subgroup vhr patient
conclus interim analysi suggest signal rigosertib
go take patient reach statist signific
enrol rate patient per month complet enrol
extend remain hope posit outcom
howev short-term compani need address capit need
lower rate hold buy remov
inspir prior on-tim trial patient random rigosertib vs
standard care intent treat popul demonstr hazard ratio hr
howev subgroup analys patient high risk high
risk diseas hr vhr demonstr hr hr continu
improv patient stratifi patient subgroup
surviv benefit month inspir trial origin design enrol
patient hr vhr diseas power achiev hr
reduct risk death trial design two shot goal
approv reach statist signific either popul subgroup
vhr patient interim analysi event independ data monitor
committe dmc result recommend trial continu enrol
increas patient endpoint trial chang
vhr group analyz far patient enrol
vhr group
click full note
due new tax law reiter buy price target
core ep exclud one-tim tax benefit match consensu
solid quarter view final piec strong year
ep success integr two excel
merger-of-equ baylak corp acquisit
first menasha bancshar posit lead independ
bank demograph attract area green valley
ep directli benefit new tax law lower effect
tax rate neg impact higher employe expens indirect
effect new tax law balanc impact posit
view rais ep estim
reflect earn momentum maintain price target
price target price-to-earnings would versu
small-cap peer believ deserv premium valuat base
superior non-interest incom contribut core deposit fund
includ non-recur net tax benefit versu consensu
view solid quarter net interest margin nim
still-strong help favor outcom loan
previous mark acquisit credit qualiti remain solid view
net chargeoff averag loan non-performing asset equal
loan core effici ratio
partli due incent compens
expect core effici ratio increas regard
manag cost consciou unemploy rate market area
wisconsin low situat exacerb recent
wage increas given competitor employe order share part
lower tax pay new tax law
rais ep estim posit impact
lower tax rate assumpt mostli off-set neg
impact rais effici ratio assumpt page
maintain price target price target ncbss price-to-earnings
would versu peer believ deserv premium
valuat base superior non-interest incom contribut core deposit fund
net interest margin
reiter buy rate next four quarter expect stock price
appreci price target result estim total return
click full note
announc deal term
aeterna announc licens deal nr
compani receiv up-front cash payment year
macrilen patent-protect
aeterna pick royalti net sale royalti
net sale
addit aeterna also receiv one-tim payment strongbridg
follow first achiev follow commerci mileston event
achiev annual net sale
achiev annual net sale
achiev annual net sale
achiev annual net sale
achiev annual net sale
follow end patent protect unit state canada macrilen
macimorelin aeterna zentari entitl royalti net sale
countri
strongbridg fund cost world-wide pediatr develop
program run aeterna zentari customari oversight joint
steer committe joint steer committe compris four
person two appoint strongbridg aeterna
valuat adjust model base announc deal term
chang valuat price target
aeterna estim approxim test suspect aghd
conduct year across unit state canada europ file
building-out sale forc previous manag suggest februari
launch date focu shift toward build commerci sale forc
experi endocrinolog cours chang base news licens
go forward europ know aeterna file macrilen
ex-u manag previous express intent out-licens macrilen
focu sale domest chang europ rest world
repres upsid model
pediatr program aeterna receiv agreement ema pediatr
develop intend engag approv adult macrilen
note strongbridg fund cost
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
